AI assistant
Merck & Co., Inc. — Director's Dealing 2019
Aug 12, 2019
284_dirs_2019-08-12_84495380-1564-4251-9dfb-202ab5a26514.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2019-08-08
Reporting Person: DeLuca Richard R. (EVP&Pres, Merck Animal Heallth)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-08-08 | Common Stock | M | 31699 | — | Acquired | 103222.81 | Direct |
| 2019-08-08 | Common Stock | S | 31699 | $85.0118 | Disposed | 71523.81 | Direct |
| 2019-08-09 | Common Stock | M | 6427 | — | Acquired | 77950.81 | Direct |
| 2019-08-09 | Common Stock | S | 6427 | $85.0863 | Disposed | 71523.81 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-08-08 | Stock Option (Right to Buy) | $39.29 | M | 31699 | Disposed | 2022-05-01 | Common Stock (31699) | Direct |
| 2019-08-09 | Stock Option (Right to Buy) | $39.29 | M | 6427 | Disposed | 2022-05-01 | Common Stock (6427) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock - 401(k) Plan | 1080.2593 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.0000 to $85.0450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.0500 to $85.1450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: Holdings include shares acquired in dividend reinvestment transactions.
F4: Includes shares acquired and dividends earned through July 8, 2019, in the Merck U.S. Savings Plan, a 401(k) plan.
F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.